At the end of July 2023 NHSE published guidance titled “National medicines optimisation opportunities 2023/24”. This guidance describes the 16 national medicines optimisation opportunities for the NHS in 2023/24, and signposts to resources to help with their implementation. It recommends Integrated Care Boards (ICBs) choose at least five medicines optimisation opportunities to focus and deliver on alongside their local medicines optimisation priorities. Progress against chosen opportunities will be reviewed using available data.

This report has data at SICBL, ICB and Commissioning Region level and focuses on the antibacterial MO opportunities:

  • Reducing course length of antimicrobial prescribing
  • Switching intravenous antibiotics to oral

NHS England Aims:

  • Reduce course length of antimicrobial prescribing to 5 days for specific common infections, where appropriate: sinusitis, sore throat, COPD infective exacerbation, cough (acute), pneumonia (community-acquired) and otitis media.
  • To reduce the number of patients receiving IV antibiotics past the point at which they meet the switch criteria and to reduce the proportion of IV doses.

The report is provided to NHS colleagues only, please do not share outside the NHS.

If you have problems accessing this file due to a security warning, please see this advice on opening the file. For further assistance, please email us at nuth.nyrdtc.rxsupp@nhs.net.



Data period

January 2021 to December 2023